PPT-Switching from dual antiplatelet therapy with aspirin plus a P2Y

Author : brown | Published Date : 2023-11-11

12 inhibitor to dual pathway inhibition with aspirin plus vasculardose rivaroxaban The Switching AntiPlatelet and AntiCoagulant Therapy SWAPAC Study Luis OrtegaPaz

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Switching from dual antiplatelet therapy..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Switching from dual antiplatelet therapy with aspirin plus a P2Y: Transcript

12 inhibitor to dual pathway inhibition with aspirin plus vasculardose rivaroxaban The Switching AntiPlatelet and AntiCoagulant Therapy SWAPAC Study Luis OrtegaPaz MD PhD 1 Francesco Franchi MD. 978 978 915 915 978 Input Torque Capacity lbft 14502050 2250 14501650 14501650 14501650 14501650 15501750 1650 15501750 15501750 Engine Coupling Dry Clutch Dry Clutch Dry Clutch Dry Clutch Dry Clutch Dry Clutch Dry Clutch Dry Clutch Dry Clutch Dry C Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. د. حسين محمد جمعة . اختصاصي الامراض الباطنة . . البورد العربي . كلية طب الموصل . . . . 2011. . . Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . (EINSTEIN CHOICE). Ryan Sparks, . PharmD. , BCPS. PGY2 Cardiology Resident. WakeMed. Health & . Hosptials. Raleigh, NC. Dr. . Ryan Sparks (presenter). Current PGY2 Cardiology Resident at . WakeMed. ASA – NSAID Drug/Drug Interaction. Working Group: . Alan D. Bell, MD, CCFP; Wee . Shian. Chan, MD, FRCP. Objectives. Interpret. . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet therapy in patients . Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group: Jean-François Tanguay , MD, CSPQ, FRCP(C), FACC, FAHA, FESC; Michael P. Love, MB, ChB, MD, MRCP; and Robert C. Welsh, MD, FRCP, FACC Physiologically; when platelets are activated, they undergo a sequence of reactions that are essential for hemostasis & important for the healing of damaged blood vessels. These reactions include:. Presenter: . Meng-Jiun. . Chiou. 5Sep2017. 1. Introduction. Lifelong . antiplatelet. treatment is recommended after . ischaemic. vascular events, on the basis of trials done mainly in patients younger than 75 years. . People with diabetes have a 2 to 4 fold higher risk of dying from cardiovascular disease. People with diabetes have a complex procoagulant state, which contributes to the increased risk of atheroscler March 28, 2022. Disclosures. Present Research/Grant Funding. Janssen/Johnson & Johnson. CSL Behring. SCAD Alliance. Baim. Institute. Patents and Stocks: . None. Equity: . nference. , Inc. . Dyad Medical.

Download Document

Here is the link to download the presentation.
"Switching from dual antiplatelet therapy with aspirin plus a P2Y"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.